The introduction of interferon beta therapies more than 20 years ago marked a milestone in the treatment of
relapsing-remitting multiple sclerosis (RRMS) with a significant impact on the approach to modern multiple
sclerosis (MS) care. The continuous development of interferon’s over the past two decades outlines a journey
with increased understanding of the pharmacodynamics and pharmacokinetic mechanisms of interferons, leading
to innovative formulations with an improved benefit/risk profile.
Modern Medicine – March 2018